Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 12/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791838 | 0.91 | KDR (0.44) | IRAK4PDE10APDGFRBFBP1EGFR | |
| SCHEMBL5653371 | 0.84 | PDE10A (0.47) | PDE10APDGFRBCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5651040 | 0.81 | FLT1 (0.41) | PDE10APDGFRB | |
| SCHEMBL4778828 | 0.79 | PDE10A (0.43) | PDE10APDGFRBEGFRCYP1A2CYP3A4 | |
| SCHEMBL4980334 | 0.79 | PDE10A (0.49) | PDE10ACYP3A4CYP2C19 | |
| SCHEMBL5652542 | 0.78 | PDGFRB (0.47) | PDE10APDGFRBCYP3A4 | |
| SCHEMBL4791761 | 0.77 | PDE10A (0.41) | PDE10ASLC2A1PDGFRBFBP1ABCG2 | |
| SCHEMBL4982681 | 0.76 | PDGFRB (0.44) | PDE10APDGFRB | |
| SCHEMBL5653771 | 0.74 | KDR (0.41) | PDE10APDGFRB | |
| SCHEMBL5651961 | 0.73 | PDE10A (0.56) | PDE10APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991540-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2007-11-15 | — | — | US | disclosed |
| WO-2007098214-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265270-A1 | Cinnoline derivatives as phosphodiesterase 10 inhibitors | PDE7A, PDE10A, PDE7B | IRAK4 2730/4885PDE10A 2/4885SLC2A1 2899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.